OLX101 / OliX Pharma, Hugel - LARVOL DELTA

Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery (clinicaltrials.gov) - P2 | N=22 | Completed | Sponsor: Olix Pharmaceuticals, Inc. | Phase classification: P2a ➔ P2

Phase classification • Surgery

Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery (clinicaltrials.gov) - P2a | N=22 | Completed | Sponsor: Olix Pharmaceuticals, Inc. | Active, not recruiting ➔ Completed | Trial primary completion date: Jun 2022 ➔ Jan 2023

Surgery • Trial completion • Trial primary completion date

the Hypertrophic Scar Prevention of BMT101. (clinicaltrials.gov) - P2a | N=20 | Terminated | Sponsor: Hugel | N=30 ➔ 20 | Trial completion date: Aug 2023 ➔ May 2023 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2022 ➔ May 2023; Internal reasons

Enrollment change • Trial completion date • Trial primary completion date • Trial termination

Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery (clinicaltrials.gov) - P2a | N=30 | Active, not recruiting | Sponsor: Olix Pharmaceuticals, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Surgery

the Hypertrophic Scar Prevention of BMT101. (clinicaltrials.gov) - P2a | N=30 | Recruiting | Sponsor: Hugel | Trial completion date: Aug 2022 ➔ Aug 2023 | Trial primary completion date: Dec 2021 ➔ Dec 2022

Trial completion date • Trial primary completion date

Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery (clinicaltrials.gov) - P2a | N=30 | Recruiting | Sponsor: Olix Pharmaceuticals, Inc. | Trial completion date: Mar 2023 ➔ Sep 2023 | Trial primary completion date: Dec 2021 ➔ May 2022

Trial completion date • Trial primary completion date

Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery (clinicaltrials.gov) - P2a; N=30; Recruiting; Sponsor: Olix Pharmaceuticals, Inc.; Initiation date: May 2021 ➔ Aug 2021

Clinical • Trial initiation date

the Hypertrophic Scar Prevention of BMT101. (clinicaltrials.gov) - P2a; N=30; Recruiting; Sponsor: Hugel; Trial completion date: Dec 2020 ➔ Aug 2022; Trial primary completion date: Aug 2020 ➔ Dec 2021

Trial completion date • Trial primary completion date

Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery (clinicaltrials.gov) - P2a; N=30; Recruiting; Sponsor: Olix Pharmaceuticals, Inc.

Clinical • New P2a trial